TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18697376
Drug: Diclofenac rectal
Normalized name: diclofenac Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac rectal suppositories (50 mg, two tablets)
Study: 18697376
Drug: Placebo rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rectal suppositories (two look-alike tablets)
Study: 15041587
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral dextromethorphan 30 mg
Study: 11735011
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg and metronidazole 500 mg
Study: 11735011
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous prophylaxis
Study: 9428917
Drug: CAF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (cyclophosphamide 600 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., fluorouracil 600 mg/m2 i.v.)
Study: 9428917
Drug: DES-CAF (DES
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-CAF (DES 1 mg orally days 1-3, CAF on day 4)
Study: 30673725
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg/day) for 20 consecutive days
Study: 26588214
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders
Study: 24506498
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa once monthly (QM)
Study: 16996583
Drug: Tegafur‐Uracil 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur‐Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV weekly on day 1 concurrent with standard radiotherapy (Group A)
Study: 16996583
Drug: Carboplatin alone
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin alone concurrent with standard radiotherapy (Group B)
Study: 15498381
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries
Study: 15498381
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based combination chemotherapy (control)
Study: 3107378
Drug: Citrate as
Normalized name: orphenadrine citrate 25 mg / aspirin 385 mg / caffeine 30 mg ORAL TABLET [Orphenadrine Citrate Aspirin Caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate as the sole anticoagulant for periods of 2 months
Study: 3107378
Drug: Heparin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin as an anticoagulant
Study: 31188694
Drug: CHO (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (1.2 g CHO·kg body mass‐1)
Study: 28197932
Drug: Triptorelin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.2 mg
Study: 28197932
Drug: Triptorelin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.3 mg
Study: 28197932
Drug: Triptorelin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.4 mg
Study: 28197932
Drug: Triptorelin doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin doses (0.2, 0.3, 0.4 mg)
Study: 23890595
Drug: aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole once-monthly 200mg
Study: 23890595
Drug: aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole once-monthly 300mg
Study: 23890595
Drug: aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole once-monthly 400mg
Study: 23890595
Drug: aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole once-monthly (any dose)
Study: 18047523
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg subcutaneously at week 0, then 40 mg every other week)
Study: 18047523
Drug: Methotrexate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5 mg orally, increased as needed to 25 mg weekly)
Study: 10848924
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg orally twice daily for 4 weeks)
Study: 10848924
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral administration for 4 weeks)
Study: 8229102
Drug: Self-administered Quality-of-Life
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Quality-of-Life after Myocardial Infarction (QLMI) questionnaire
Study: 31777212
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d) plus NSAID
Study: 29893296
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine (5mg/kg/day) and topical terbinafine 1% applied twice daily for 4 weeks
Study: 27515978
Drug: Guselkumab IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab IV (0.03-10 mg/kg)
Study: 27515978
Drug: Guselkumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab SC (10-300 mg)
Study: 27515978
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC (10, 30, 100, 300 mg)
Study: 23281755
Drug: Chickens slaughtered
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chickens slaughtered at 2000 g
Study: 23281755
Drug: Chickens slaughtered
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chickens slaughtered at 1500 g
Study: 18390635
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 6 weeks
Study: 16199251
Drug: Cefdinir (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (once daily n = 569 or twice daily n = 1086) for 5 or 10 days
Study: 16199251
Drug: Penicillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (4 times daily n = 1096) for 10 days
Study: 12451319
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 or 20 mg/d)
Study: 7476741
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of plain water two and half hours before surgery (Group 1)
Study: 28836341
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (OD)
Study: 25499095
Drug: Caltrate 600
Normalized name: Caltrate 600 + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 1 tablet/day
Study: 25499095
Drug: Caltrate 600
Normalized name: Caltrate 600 + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate 600 mg elemental calcium; 125 IU vitamin D3, 2 tablets/day
Study: 22416402
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution and 10% glucose solution (1:1 ratio)
Study: 22416402
Drug: Sterofundin-G-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterofundin-G-5
Study: 22416402
Drug: Remaksol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaksol (800 ml/day)
Study: 15196263
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB), 3 times weekly, followed by gradual withdrawal of immunosuppressive drugs.
Study: 15196263
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of p336‐351 linked to cholera toxin B subunit (CTB)
Study: 11476424
Drug: Eccentric overload
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric overload training (12-week treatment protocol)
Study: 3171265
Drug: Medical vagotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical vagotomy (0.5 mg of atropine and 50 mg of hexamethonium bromide, injected three times at two hour intervals intramuscularly)
Study: 21601833
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg once a day)
Study: 1687129
Drug: Formoterol (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (with inhaled steroids reintroduced)
Study: 15876899
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release 300 mg/d
Study: 27324341
Drug: Probiotic SYNBIO(®)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic SYNBIO(®) vaginal suppositories (Lactobacillus rhamnosus IMC 501(®) and Lactobacillus paracasei IMC 502(®)) administered daily for 7 days
Study: 27324341
Drug: Probiotic SYNBIO(®)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic SYNBIO(®) vaginal suppositories
Study: 24804879
Drug: Adrenocorticotropin hormone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenocorticotropin hormone, epinephrine, and norepinephrine
Study: 18367110
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy followed by interferon treatment
Study: 8993854
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor antagonists (AT1 antagonists)
Study: 8993854
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor antagonists (AT1 antagonists) with diuretic
Study: 4033401
Drug: Dehydration (D)
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydration (D) with 40 mg of furosemide
Study: 20508478
Drug: PHiD‐CV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV and MMRV vaccine
Study: 20508478
Drug: DTPa‐HBV‐IPV/Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa‐HBV‐IPV/Hib and MMRV vaccines
Study: 20508478
Drug: PHiD‐CV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV and DTPa‐HBV‐IPV/Hib vaccine
Study: 15315997
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 IU) daily
Study: 9296325
Drug: Pranlukast (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (300 mg) administered in the evening after a high fat meal
Study: 9296325
Drug: Pranlukast (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (300 mg) administered in the morning after a high fat meal
Study: 8191447
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of chloramphenicol eyedrops (0.5% eye drops, one drop hourly/every two hours for three days, thereafter every 4‐6 hours)
Study: 8191447
Drug: Simplified dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified dosage of chloramphenicol eyedrops (four times a day)
Study: 3075473
Drug: Euro‐Collins' solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euro‐Collins' solution (ECS; n = 9)
Study: 3075473
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (RS; n = 9)
Study: 22617860
Drug: Modafinil 255
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 255 mg daily
Study: 22617860
Drug: Modafinil 340
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 340 mg daily
Study: 22617860
Drug: Modafinil 425
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 425 mg daily
Study: 22617860
Drug: Modafinil 510
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 510 mg daily
Study: 22015077
Drug: Elvitegravir 150
Normalized name: elvitegravir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvitegravir 150 mg once daily
Study: 16305290
Drug: Bitter-orange dried-fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter-orange dried-fruit extract (450 mg standardized to 27 mg of m- or p-synephrine)
Study: 7534217
Drug: Atropine 10
Normalized name: Isopto Atropine 10 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 10 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 12)
Study: 7534217
Drug: Atropine 20
Normalized name: Minims Homatropine 20 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 13)
Study: 7534217
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg.kg‐1 (n = 11)
Study: 913121
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg indomethacin daily
Study: 30768161
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day high-dose dual therapy (esomeprazole 40 mg three times daily and amoxicillin 750 mg four times daily for 14 days)
Study: 30768161
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day non-bismuth quadruple therapy (esomeprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days)
Study: 30768161
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day high-dose dual therapy
Study: 30768161
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day non-bismuth quadruple therapy
Study: 25462663
Drug: Stimulant Craving
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant Craving Questionnaire (STCQ) for methamphetamine users
Study: 25462663
Drug: Stimulant Craving
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant Craving Questionnaire (STCQ) for cocaine users
Study: 21856349
Drug: HPV co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV co-administered with HepB
Study: 8167653
Drug: Postexercise glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexercise glucose ingestion (100 g glucose polymer drink)
Study: 8167653
Drug: Postexercise glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexercise glucose ingestion with potassium chloride (3 g KCl)
Study: 2850604
Drug: s.c. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection of 8 micrograms alsactide
Study: 2850604
Drug: s.c. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection of 10 micrograms alsactide
Study: 2850604
Drug: s.c. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection of 20 micrograms alsactide
Study: 2850604
Drug: i.v. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. injection of 2 micrograms alsactide
Study: 2850604
Drug: i.v. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. injection of 4 micrograms alsactide
Study: 2850604
Drug: i.v. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. injection of 8 micrograms alsactide
Study: 19335435
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment applied twice daily for 8 weeks
Study: 3052188
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of Rhinalar (less propylene glycol)
Study: 3052188
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of Rhinalar
Study: 28656612
Drug: Caloric vestibular
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric vestibular stimulation (CVS) device (TNM™), 3-month treatment
Study: 24257722
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g whey protein
Study: 25979566
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g whey protein
Study: 25979566
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g whey protein
Study: 25979566
Drug: All conditions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All conditions (20, 40, 60, 80 g whey protein)
Study: 23052408
Drug: Sirolimus administered
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus administered simultaneously with tacrolimus
Study: 23052408
Drug: Sirolimus administered
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus administered staggered after tacrolimus
Study: 23052408
Drug: Tacrolimus administered
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus administered simultaneously with sirolimus
Study: 23052408
Drug: Tacrolimus administered
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus administered staggered before sirolimus
Study: 19222510
Drug: Tonabersat 20
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonabersat 20 mg daily for 2 weeks and 40 mg daily for a further 10 weeks
Study: 12846595
Drug: Subcutaneous melagatran
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous melagatran (3mg)
Study: 12846595
Drug: Oral ximelagatran
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ximelagatran (24mg)
Study: 10958095
Drug: Metoclopramide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.3 mg x kg(‐1))
Study: 10958095
Drug: Dimenhydrinate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (1 mg x kg(‐1))
Study: 10958095
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimenhydrinate and metoclopramide
Study: 8836333
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (local nasal immunotherapy with birch-alder allergens in powder form)
Study: 4072649
Drug: Meticillin 1
Normalized name: methicillin
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meticillin 1 g X 4 intravenously on the day of operation
Study: 23902481
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² administered once a week for 4 weeks)
Study: 21816030
Drug: RTS, S/AS01
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS, S/AS01 malaria vaccine
Study: 19394194
Drug: Direct Treatment
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Treatment Model (DT)
Study: 19394194
Drug: Collaborative-Consultation Treatment
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collaborative-Consultation Treatment Model (CC)
Study: 19394194
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment Model (CT)
Study: 16928222
Drug: PBAT (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBAT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin‐clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d.)
Study: 16928222
Drug: PBMT (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.)
Study: 15173146
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g monthly)
Study: 11340690
Drug: Intranasal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal triamcinolone acetonide 220 micrograms/day for six months
Study: 11340690
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine 10 mg/day
Study: 11340690
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate 400 micrograms/day
Study: 8076759
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (8.4-336 megaunits)
Study: 28848330
Drug: Yogurt supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt supplemented with Lactobacillus paracasei N1115, 300 mL/d for 12 weeks
Study: 25187210
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg intranasal scopolamine gel (INSCOP)
Study: 25187210
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intranasal scopolamine gel (INSCOP)
Study: 25187210
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intranasal scopolamine gel (INSCOP)
Study: 19359109
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone treatment
Study: 8123410
Drug: i.v. clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. clonidine 30 micrograms diluted in saline to a total volume of 5 ml, repeated every 5 min up to a maximum dose of 90 micrograms
Study: 8123410
Drug: saline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 5 ml (placebo solution), repeated every 5 min up to a maximum of three boluses
Study: 8123410
Drug: saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline (placebo) after initial clonidine treatment
Study: 31039153
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of linezolid
Study: 31039153
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of linezolid
Study: 31039153
Drug: Long-term linezolid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term linezolid treatment
Study: 29016675
Drug: Team sport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team sport group ingesting a drink high in protein (18 g) immediately and 3 h after each training session (TS-HP, n = 13)